de la Puente, P
Muz, B
Jin, A
Azab, F
Luderer, M
Salama, N N
Azab, A K
Article History
First Online: 26 February 2016
Competing interests
: Dr Azab receives research support from Verastem, Selexys, Karyopharm, Cell Works, Cleave Bioscience, Glycomimetics, Abbvie and Seattle Genetics; and is the founder and owner of Targeted Therapeutics LLC and Cellatrix LLC. Dr de la Puente is co-founder of Cellatrix LLC. The remaining authors declare no conflicts of interest.